SAN DIEGO , May 10, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2017 and provided an update on its corporate activities and

SAN DIEGO --(BUSINESS WIRE)--Apr. 25, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Taylor Sandison , M.D., M.P.H., has been named chief medical officer (CMO) of the company. Dr.

SAN DIEGO --(BUSINESS WIRE)--Apr. 17, 2017-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from nonclinical studies of its novel echinocandin antifungal CD101 and its Cloudbreak TM antibacterial

CARB-X Funding to Advance Novel First-in-Class Bispecific Immunotherapy to Fight Multi-drug Resistant Bacterial Infections SAN DIEGO --(BUSINESS WIRE)--Mar. 30, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today

SAN DIEGO , March 29, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017 , from 8:30 a.m. to 11:30 a.m. EDT ( 5:30 a.m. to 8:30 a.m.

SAN DIEGO , March 15, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full year ended December 31, 2016 and provided an update on its

Further Development of CD101 Topical for VVC to be discontinued CD101 IV development program in candidemia and invasive candidiasis (including Phase 2 STRIVE trial) continuing and remains on track Company to Host Conference Call Today at 5:30 a.m. PT SAN DIEGO , Feb.

Topline Data Expected in First Quarter 2017 SAN DIEGO --(BUSINESS WIRE)--Jan. 4, 2017-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the completion of patient enrollment in the RADIANT trial, a Phase 2

Data Showcase Compound’s Discovery through Development and Potential to Expand Echinocandin Utility Across Multiple Infectious-Disease Indications SAN DIEGO --(BUSINESS WIRE)--Dec. 14, 2016-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including

SAN DIEGO --(BUSINESS WIRE)--Nov. 28, 2016-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical and clinical studies evaluating its novel echinocandin antifungal CD101 will be